We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Vascular Endothelium Changes After Bariatric Surgery (Endothelial Progenitor Cells) (EPC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01213940
Recruitment Status : Unknown
Verified August 2013 by William Richards, University of South Alabama.
Recruitment status was:  Recruiting
First Posted : October 4, 2010
Last Update Posted : August 14, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:
Improvement in cardiovascular mortality is related to changes in pathologic autoantibodies and in the number of circulating functional replicative competent endothelial progenitor cells (EPC's) after bariatric surgery.

Condition or disease Intervention/treatment
Type 2 Diabetes Behavioral: pre-bariatric weight loss program Procedure: bariatric surgery

Detailed Description:
Same as above

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Vascular Endothelium Changes After Bariatric Surgery
Study Start Date : September 2010
Estimated Primary Completion Date : September 2013
Estimated Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
baratric surgery
surgery vs.weight loss program 6 months prior to bariatric surgery
Procedure: bariatric surgery
bariatric surgery for weight loss
pre-bariatric weight loss program
weight loss program prior to bariatric surgery
Behavioral: pre-bariatric weight loss program
standard 6 month physician directed pre-bariatric weight loss program
Other Name: weight loss program

Outcome Measures

Primary Outcome Measures :
  1. Change in plasma autoantibody levels [ Time Frame: 6 months ]
    Primary outcome is the change in plasma autoantibody levels (endothelial barrier function) 6 months after enrollment to surgery (LRYGB) or to standard medical therapy (SMT).

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Type 2 Diabetes, Glucose > 200mg/dl, currently be ing treated with oral medications and HGA1c . 6.5, and BMI .35.

Exclusion Criteria:

  • Type 1 Diabetes
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01213940

United States, Alabama
University of South Alabama Recruiting
Mobile, Alabama, United States, 36617
Contact: William O Richards, MD    251-471-7993    brichards@usouthal.edu   
Sponsors and Collaborators
University of South Alabama
American Society for Metabolic and Bariatric Surgery
Principal Investigator: William O Richards, MD University of South Alabama, Department of Surgery
More Information

Responsible Party: William Richards, Professor and Chairman of the Department of Surgery, University of South Alabama
ClinicalTrials.gov Identifier: NCT01213940     History of Changes
Other Study ID Numbers: 10-131
First Posted: October 4, 2010    Key Record Dates
Last Update Posted: August 14, 2013
Last Verified: August 2013